Design, expression, and characterization of a novel dendritic cell-targeted proteins

Biopolymer-based Carriers for DNA Vaccine Design

Over the last 30 years, genetically engineered DNA has been tested as novel vaccination strategy against various diseases, including human immunodeficiency virus (HIV), hepatitis B, several parasites, and cancers. However, the clinical breakthrough of the technique is confined by the low transfection efficacy and immunogenicity of the employed vaccines. Therefore, carrier materials were designed to prevent the rapid degradation and systemic clearance of DNA in the body. In this context, biopolymers are a particularly promising DNA vaccine carrier platform due to their beneficial biochemical and physical characteristics, including biocompatibility, stability, and low toxicity. This article reviews the applications, fabrication, and modification of biopolymers as carrier medium for genetic vaccines.

A systematic review of SARS-CoV-2 vaccine candidates

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is an emerging virus that is highly pathogenic and has caused the recent worldwide pandemic officially named coronavirus disease (COVID-19). Currently, considerable efforts have been put into developing effective and safe drugs and vaccines against SARS-CoV-2. Vaccines, such as inactivated vaccines, nucleic acid-based vaccines, and vector vaccines, have already entered clinical trials. In this review, we provide an overview of the experimental and clinical data obtained from recent SARS-CoV-2 vaccines trials, and highlight certain potential safety issues that require consideration when developing vaccines. Furthermore, we summarize several strategies utilized in the development of vaccines against other infectious viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV), with the aim of aiding in the design of effective therapeutic approaches against SARS-CoV-2.

Complex Emulsions by Extracting Water from Homogeneous Solutions Comprised of Aqueous Three-Phase Systems

Multiple emulsions can be obtained by binary and ternary liquid phase separation. And the use of the aqueous two-phase system provides a simple route to prepare water-in-water-in-oil (W/W/O) or water-in-water-in-water (W/W/W) multiple emulsions. It is thus expected that we can fabricate more complex emulsions by using an aqueous three-phase system. Herein, we present a simple and versatile method to generate complex emulsions based on phase separation in homogeneous droplets made up of aqueous three-phase system: poly(ethylene glycol) (PEG), poly(vinyl alcohol) (PVA) and dextran (DEX) through extracting water from droplets. We examine the formation process and the effect of mass ratio of each two components in the three phase system. Emulsion droplets with five types of morphologies, i.e., binary-core/shell, core/shell-single phase Janus, ellipsoid Janus, multicore-in-matrix and single core-double shell morphologies can be formed, depending on the mass ratio of each two components and modification of PEG with Fe₃O₄ nanoparticles. We observe transition of core/shell-single phase Janus to binary-core/shell and single core-double shell to core/shell-single phase Janus geometry with prolongation of extracting time, and obtain the geometry map for the formation of different shaped droplets. Due to different affinities of PEG, PVA and DEX to certain materials, we functionalize each compartment in the complex emulsion droplets, and apply the resulting droplet for glucose sensing and the construction of antibody-mediated targeting drug delivery. This emulsion generation method is simple and the choice for the component of the aqueous three-phase system is broad, which can be further extended to generate complex emulsions from aqueous multiphase systems.

Enhanced immunity and antiviral effects of an HBV DNA vaccine delivered by a DC-targeting protein

DNA vaccine targeting delivery to DC represents one effective strategy to improve the immunogenicity of the vaccine. In a previous study, we developed a novel DC-targeting recombinant protein that can deliver plasmid DNA to DCs by an electrostatic coupling effect and can thus improve the uptake efficiency of DCs, improving the expression of plasmid DNA in DCs. In this study, we coupled the protein with the HBV DNA vaccine pSVK-HBVA and investigated whether the immunogenicity and antiviral ability of the vaccine can be improved in HBV transgenic mice. The results show that a stronger specific immune response can be induced in mice after immunization with the coupling vaccine. The HBV DNA copy number and circulating antigen HBsAg in the serum of HBV transgenic mice were significantly decreased. Therefore, this study has demonstrated that the DC-targeting protein has the ability to improve the immunogenicity and the antiviral activity of the HBV DNA vaccine pSVK-HBVA. These findings indicate that this DC-targeting protein can be a potential method for the delivery of DNA vaccines directly to DCs.